Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB. “PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.” European Urology, July 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18614274
Loeb S and Carter HB. “Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.” Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583. Link: http://www.ncbi.nlm.nih.gov/pubmed/19879470
Loeb S. “Guideline of guidelines: prostate cancer screening.” BJU International 2014 September; 114: 323. PMID: 24981126. Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643
Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ. “PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.” Urology, June 2008 (epub). Link: http://www.ncbi.nlm.nih.gov/pubmed/18571700
Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ. “The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.” Urology 2008; 71: 1016. Link: http://www.ncbi.nlm.nih.gov/pubmed/18358515
Loeb S, Roehl KA, Catalona WJ, and Nadler RB. “Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?” BJU International, April 2008; 101: 817. Link: http://www.ncbi.nlm.nih.gov/pubmed/18321315
Loeb S. Editorial Comment on: “Outcomes of Fecal Carriage of Extended-Spectrum β-Lactamase After Transrectal Ultrasound-Guided Biopsy of the Prostate.” Urology 2014 epub. PMID 25239260. Link: http://www.ncbi.nlm.nih.gov/pubmed/25239260
Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. “Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.” BJU International 2014, July epub. PMID: 25053197. Link: http://www.ncbi.nlm.nih.gov/pubmed/25053197
Loeb S. “Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.” BJU International 2011; 108: 222. PMID: 21718432. Link: http://www.ncbi.nlm.nih.gov/pubmed/21718432
Loeb S and Schaeffer EM. “Risk Factors, Prevention, and Early Detection of Prostate Cancer.” Primary Care Clinics of North America, September 2009; 36: 603. Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157
Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR. “Genomic Predictors of Outcome in Prostate Cancer.” European Urology 2015 epub. PMID: 25913390. Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390
Barranquilla, Colombia. October 2015 Lecture Topics (all in Spanish): Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance Category: Prostate Cancer
Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, and Stattin P. “Nationwide Population-Based Study of Prostate Cancer Stage Migration Between and Within Clinical Risk Categories.” Scandinavian Journal of Urology 2014 March epub. PMID: 24581522 Link: http://www.ncbi.nlm.nih.gov/pubmed/24611795
Loeb S and Partin AW. “Randomized Trials of Prostate Cancer Screening.” Reviews in Urology, Summer 2009; 11: 179. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2777067/
Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA. “Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?” Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390. Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390
Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT. “A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.” BJU International 2014, June epub. PMID: 24952954. Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954
Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT. “Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.” BJU International 2014 Jan epub. PMID: 24712975. Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975
Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV. “Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” BJU International 2014 epub. PMID: 24661474 Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474
Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT. “Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.” BJU International 2014 Jan epub. PMID: 24712975. Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975
McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ. “Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.” BJU International June 2012; 109: 1764-9. PMID: 22017732. Link: http://www.ncbi.nlm.nih.gov/pubmed/22017732
Loeb S and Carter HB. “Should prostate-specific antigen velocity be abandoned?” Asian Journal of Andrology 2011; 12: 359. PMID: 21499277. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739355/
Loeb S and Catalona WJ. “What is the Role of Digital Rectal Examination in Men Undergoing Serial Screening of Serum PSA?” Nature Clinical Practice Urology, February 2009; 6: 68. Link: http://www.ncbi.nlm.nih.gov/pubmed/19139742
Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ. “Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.” Journal of Urology 2012; epub December. PMID: 23246478. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/
Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, and Catalona WJ. “Correlation Between Serum Prostate-Specific Antigen and Cancer Volume in Prostate Glands of Different Sizes.” Urology, September 2010 epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/20846711
Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ. “External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.” Urologic Oncology: Seminars and Original Investigations, September 2010 epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/20822930
Loeb S. “Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.” Journal of Urology March 2011; 185: 826. PMID: 21239022. Link: http://www.ncbi.nlm.nih.gov/pubmed/21239022
Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC. “Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.” Journal of Urology, 2008; 180: 1314 Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575041/
Loeb S, Gashti SN, and Catalona WJ. “Exclusion of Inflammation in the Differential Diagnosis of an Elevated Prostate-Specific Antigen (PSA).” Urologic Oncology: Seminars and Original Investigations, Jan-Feb 2009; 27: 64. Link: http://www.ncbi.nlm.nih.gov/pubmed/19111800
Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S. “Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.” Journal of Urology 2013; epub Dec 14. PMID: 24345439 Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439
Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC. “What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?” Urology 2009, Nov 19 epub. Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898
Loeb S and Partin AW. “PCA3 Urinary Biomarker for Prostate Cancer.” Reviews in Urology Fall 2010; 12: e205. PMID: 21234266. Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020285/
Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ. “Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.” Journal of Urology 2008; 179: 1340. Link: http://www.ncbi.nlm.nih.gov/pubmed/18289590
Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ. “PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.” Journal of Urology, December 2007; 178; 2348. Link: http://www.ncbi.nlm.nih.gov/pubmed/17936844
Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ. “The Association Between Total PSA and PSA Velocity.” Journal of Urology, April 2007; 177: 1298. Link: http://www.ncbi.nlm.nih.gov/pubmed/17382716
Loeb S, Roehl KA, Catalona WJ, and Nadler RB. “PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.” Journal of Urology, March 2007; 177: 899. Link: http://www.ncbi.nlm.nih.gov/pubmed/17296371
Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ. “Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.” Urology, January 2007; 69: 108. Link: http://www.ncbi.nlm.nih.gov/pubmed/17270629
Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ. “Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.” Journal of Urology, December 2006; 176: 2427. Link: http://www.ncbi.nlm.nih.gov/pubmed/17085120
Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ. “Accuracy of Prostate Weight Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).” Journal of Urology, January 2005; 173: 63-5. Link: http://www.ncbi.nlm.nih.gov/pubmed/15592029
Loeb S and Catalona WJ. “Diagnosis and Treatment of Prostate Cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate.” Medical Economics, December 2008; 85: 36. Link: http://www.ncbi.nlm.nih.gov/pubmed/19209648
Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, and Metter EM. “Should Prostate-specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.” Journal of Urology, December 2009; 182: 2646. Link: http://www.ncbi.nlm.nih.gov/pubmed/19836806